FDA 483 - Sato Pharmaceutical Co., Ltd. - July 03, 2018
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Sato Pharmaceutical Company Limited in Hachioji, Tokyo, was cited for significant deficiencies across its drug manufacturing operations. Observations included failures in quality control unit procedures, inadequate environmental monitoring in aseptic processing areas, and a lack of scientifically sound laboratory controls for container closure integrity. Additionally, the firm failed to maintain backup files for critical laboratory data, indicating systemic data integrity concerns.
ID · bda58c1f-6dfc-4c9c-a3de-38805e3581c6